Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Tecadenoson. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADORA1 known ✓ | P30542 | 9/20 | 1.00 |
| ▸ | ADORA2A | P29274 | 7/20 | 1.00 |
| ▸ | ADORA3 | P0DMS8 | 7/20 | 1.00 |
| ▸ | ADORA2B | P29275 | 4/20 | 1.00 |
| ▸ | SLC29A1 | Q99808 | 2/20 | 1.00 |
| ▸ | SLC28A1 | O00337 | 1/20 | 1.00 |
| ▸ | TSHR | P16473 | 3/20 | 0.78 |
| ▸ | PMP22 | Q01453 | 2/20 | 0.78 |
| ▸ | GAA | P10253 | 1/20 | 0.78 |
| ▸ | HTT | P42858 | 1/20 | 0.78 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.78 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.78 |
| ▸ | MEN1 | O00255 | 1/20 | 0.78 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.78 |
| ▸ | TP53 | P04637 | 1/20 | 0.78 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.78 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.78 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.77 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.77 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.77 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Tecadenoson SCHEMBL15106888 | 1.00 | ADORA1 (1.00) | ADORA1ADORA2AADORA3ADORA2BSLC29A1 | |
| Tecadenoson SCHEMBL472425 | 1.00 | ADORA1 (1.00) | ADORA1ADORA2AADORA3ADORA2BSLC29A1 | |
| Tecadenoson SCHEMBL1095647 | 1.00 | ADORA1 (1.00) | ADORA1ADORA2AADORA3ADORA2BSLC29A1 | |
| Tecadenoson SCHEMBL472549 | 1.00 | ADORA1 (1.00) | ADORA1ADORA2AADORA3ADORA2BSLC29A1 | |
| Tecadenoson SCHEMBL15106884 | 1.00 | ADORA1 (1.00) | ADORA1ADORA2AADORA3ADORA2BSLC29A1 | |
| Tecadenoson SCHEMBL12265126 | 1.00 | ADORA1 (1.00) | ADORA1ADORA2AADORA3ADORA2BSLC29A1 | |
| Tecadenoson SCHEMBL24838611 | 1.00 | ADORA1 (1.00) | ADORA1ADORA2AADORA3ADORA2BSLC29A1 | |
| Tecadenoson SCHEMBL6226634 | 1.00 | ADORA1 (1.00) | ADORA1ADORA2AADORA3ADORA2BSLC29A1 | |
| Tecadenoson SCHEMBL22349437 | 1.00 | ADORA1 (1.00) | ADORA1ADORA2AADORA3ADORA2BSLC29A1 | |
| Tecadenoson SCHEMBL7034923 | 1.00 | ADORA1 (1.00) | ADORA1ADORA2AADORA3ADORA2BSLC29A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 418 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260144879-A1 | ANTI-VIRAL AND HEPATIC-TARGETED DRUGS | AI-BIOPHARMA (FR) | 2026-05-28 | — | — | US | claimed |
| WO-2025111482-A1 | COMPLEXING AGENT SALT FORMULATIONS OF PHARMACEUTICAL COMPOUNDS AT LOW STOICHIOMETRIC RATIOS | BEXSON BIOMEDICAL, INC. (US) | 2025-05-30 | — | — | WO | claimed |
| US-20240139325-A1 | ANTI-VIRAL AND HEPATIC-TARGETED DRUGS | AI-BIOPHARMA (FR) | 2024-05-02 | — | — | US | claimed |
| EP-4178948-A2 | FUNCTIONALIZED ISONITRILES AND PRODUCTS, PREPARATION AND USES THEREOF | Universidade de Santiago de Compostela (ES) | 2023-05-17 | — | — | EP | claimed |
| EP-4045504-A1 | ANTI-VIRAL AND HEPATIC-TARGETED DRUGS | Ai-biopharma (FR) | 2022-08-24 | — | — | EP | claimed |
| CN-114376962-A | Drug-loaded nanofiber for acupuncture point thread embedding material and preparation method and application thereof | 上海市第四人民医院 | 2022-04-22 | — | — | CN | claimed |
| WO-2022023496-A2 | FUNCTIONALIZED ISONITRILES AND PRODUCTS, PREPARATION AND USES THEREOF | UNIVERSIDADE DE SANTIAGO DE COMPOSTELA (ES) | 2022-02-03 | — | — | WO | claimed |
| WO-2021074443-A1 | ANTI-VIRAL AND HEPATIC-TARGETED DRUGS | AI-BIOPHARMA (FR) | 2021-04-22 | — | — | WO | claimed |
| US-20200276312-A1 | Elimination of chronic pain by chronic activation of adenosine receptor type A1 in peripheral sensory neurons | UNIV ROCHESTER (US) | 2020-09-03 | — | — | US | claimed |
| WO-2019178267-A2 | INDUCTIVE REGENERATION OF THE AIRWAY BY TRANSCRIPTIONAL FACTOR MODULATION OF GLANDULAR MYOEPITHELIAL STEM CELLS | UNIVERSITY OF IOWA RESEARCH FOUNDATION (US) | 2019-09-19 | — | — | WO | claimed |
| WO-2008063323-A2 | TREATMENT WITH ANTIARRHYTHMICS AND OMEGA-3 FATTY ACIDS AND A COMBINATION PRODUCT THEREOF | RELIANT PHARMACEUTICALS, INC. (US) | 2008-05-29 | — | — | WO | claimed |
| WO-2007073855-A1 | USE OF ADENOSINE A1 RECEPTOR AGONISTS FOR THE PROTECTION OF RENAL CELLS AGAINST TOXIC EFFECTS CAUSED BY AMINOGLYCOSIDES DURING TREATMENT OF INFECTIOUS DISEASES | BAYER HEALTHCARE AG (DE) | 2007-07-05 | — | — | WO | claimed |
| WO-2007061529-A1 | LYOPHILIZATION PROCESS AND PRODUCTS OBTAINED THEREBY | SCIDOSE LLC. (US) | 2007-05-31 | — | — | WO | claimed |
| US-20070116729-A1 | Lyophilization process and products obtained thereby | SCIDOSE LLC | 2007-05-24 | — | — | US | claimed |
| US-20050074425-A1 | Method for delivering polymerized therapeutic agent compositions and compositions thereof | POLYCORD, INC. (US) | 2005-04-07 | — | — | US | claimed |
| WO-2005002597-A1 | METHOD FOR DELIVERING POLYMERIZED THERAPEUTIC AGENT COMPOSITIONS AND COMPOSITIONS THEREOF | POLYCORD, INC. (US) | 2005-01-13 | — | — | WO | claimed |
| WO-2004056181-A1 | ORGAN PRECONDITIONING, ARREST, PROTECTION, PRESERVATION AND RECOVERY (2) | GLOBAL CARDIAC SOLUTIONS PTY LTD (AU) | 2004-07-08 | — | — | WO | claimed |
| WO-2004056180-A1 | ORGAN PRECONDITIONING, ARREST, PROTECTION, PRESERVATION AND RECOVERY (1) | GLOBAL CARDIAC SOLUTIONS PTY LTD (AU) | 2004-07-08 | — | — | WO | claimed |
| EP-0992510-B1 | N6 heterocyclic substituted adenosine derivatives | CV THERAPEUTICS INC (US) | 2003-03-12 | — | — | EP | claimed |
| US-20020037871-A1 | Pharmaceutical use of adenosine agonists | CAN-FITE BIOPHARMA LTD. (IL) | 2002-03-28 | — | — | US | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20260144879-A1 | ANTI-VIRAL AND HEPATIC-TARGETED DRUGS | HAVCR2, NR1H4, NR1H3 | ADORA1 515/4885ADORA2A 1902/4885ADORA3 558/4885 |
| US-20020037871-A1 | Pharmaceutical use of adenosine agonists | ADORA1, ADORA2A, ADORA3 | ADORA1 1/4885ADORA2A 2/4885ADORA3 3/4885 |
| US-20240139325-A1 | ANTI-VIRAL AND HEPATIC-TARGETED DRUGS | SLC10A1, HAVCR2, HDGF | ADORA1 4210/4885ADORA2A 4586/4885ADORA3 3777/4885 |
| US-20200276312-A1 | Elimination of chronic pain by chronic activation of adenosine receptor type A1 in peripheral sensory neurons | P2RX3, P2RX1, P2RX2 | ADORA1 4/4885ADORA2A 8/4885ADORA3 13/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.